About: Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
Creator	Torres, A Artigas, A Blanquer, J Granada, R Martín, M Vidaur, L Diaz, E Rodriguez, A Sirvent, J Vallés, J Bermejo-Martin, J Broggi, Moisès Despí, Joan Despí, Spain Figueira, J Martín-Loeches, I Rodriguez, Sant, Joan Suarez, D Vergara-Serrano, J
Source	PMC
abstract	PURPOSE: To determine whether macrolide-based treatment is associated with mortality in critically ill H1N1 patients with primary viral pneumonia. METHODS: Secondary analysis of a prospective, observational, multicenter study conducted across 148 Intensive Care Units (ICU) in Spain. RESULTS: Primary viral pneumonia was present in 733 ICU patients with pandemic influenza A (H1N1) virus infection with severe respiratory failure. Macrolide-based treatment was administered to 190 (25.9 %) patients. Patients who received macrolides had chronic obstructive pulmonary disease more often, lower severity on admission (APACHE II score on ICU admission (13.1 ± 6.8 vs. 14.4 ± 7.4 points, p < 0.05), and multiple organ dysfunction syndrome less often (23.4 vs. 30.1 %, p < 0.05). Length of ICU stay in survivors was not significantly different in patients who received macrolides compared to patients who did not (10 (IQR 4–20) vs. 10 (IQR 5–20), p = 0.9). ICU mortality was 24.1 % (n = 177). Patients with macrolide-based treatment had lower ICU mortality in the univariate analysis (19.2 vs. 28.1 %, p = 0.02); however, a propensity score analysis showed no effect of macrolide-based treatment on ICU mortality (OR = 0.87; 95 % CI 0.55–1.37, p = 0.5). Moreover, the sensitivity analysis revealed very similar results (OR = 0.91; 95 % CI 0.58–1.44, p = 0.7). A separate analysis of patients under mechanical ventilation yielded similar results (OR = 0.77; 95 % CI 0.44–1.35, p = 0.4). CONCLUSION: Our results suggest that macrolide-based treatment was not associated with improved survival in critically ill H1N1 patients with primary viral pneumonia.
has issue date	2013-01-24(xsd:dateTime)
bibo:doi	10.1007/s00134-013-2829-8
bibo:pmid	23344833
has license	no-cc
sha1sum (hex)	5ac935d6175ae776741fd6f63925f108e12bee9c
schema:url	https://doi.org/10.1007/s00134-013-2829-8
resource representing a document's title	Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
has PubMed Central identifier	PMC7094901
has PubMed identifier	23344833
schema:publication	Intensive Care Med
resource representing a document's body	covid:5ac935d6175ae776741fd6f63925f108e12bee9c#body_text
is schema:about of	named entity 'bacterial' named entity 'H1N1' named entity '0.7' named entity 'OUR' named entity 'REVEALED' named entity 'WORKING GROUP' named entity 'SIMILAR' named entity 'ARTIGAS' named entity 'ANALYSIS' named entity 'Conclusion' named entity 'patients' named entity 'viral pneumonia' named entity 'critically ill' named entity 'H1N1' named entity 'ICU' named entity 'ICU' named entity 'Spain' named entity '2009 pandemic' named entity 'CAP' named entity 'chronic renal disease' named entity 'nasopharyngeal swab' named entity 'ICU' named entity 'complicated by pneumonia' named entity 'macrolides' named entity 'macrolide' named entity 'hematological disease' named entity 'Society of Critical Care Medicine' named entity 'viral pneumonia' named entity 'H1N1' named entity 'influenza virus' named entity 'logistic regression' named entity 'intensive care' named entity 'New Zealand' named entity 'infection' named entity 'infection' named entity 'macrolides' named entity 'antibiotics' named entity 'respiratory failure' named entity 'oliguria' named entity 'cytokine' named entity 'macrolides' named entity 'CAP' named entity 'CRRT' named entity 'macrolide' named entity 'viral pneumonia' named entity 'macrolides' named entity 'Clarithromycin' named entity 'zanamivir' named entity 'viral load' named entity 'macrolides' named entity 'immunological' named entity 'ETA' named entity 'pandemic influenza' named entity 'H1N1' named entity 'infection' named entity 'pregnancy' named entity 'influenza' named entity 'placebo-controlled trial' named entity 'susceptibility testing' named entity 'treatment groups' named entity 'ICU' named entity 'prednisolone'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software